8-KOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Corporate Update (Mar 4, 2008)

Filed March 4, 2008For Securities:BIIB

Summary

Biogen Idec Inc. announced on March 4, 2008, the successful completion of a public offering of $1.0 billion in aggregate principal amount of senior notes. This offering was divided into two tranches: $450 million of 6.000% Notes due March 1, 2013, and $550 million of 6.875% Notes due March 1, 2018. The notes were registered under a Form S-3 filing, indicating they were offered under a shelf registration statement. The primary purpose of this filing is to report the completion of this significant debt financing. Investors should note the specific interest rates and maturity dates for each tranche of notes, which provide insight into the company's cost of borrowing and long-term capital structure. The inclusion of the underwriting agreement and supplemental indenture as exhibits provides transparency into the terms and conditions of this debt issuance.

Key Highlights

  • 1Biogen Idec Inc. completed a $1.0 billion debt offering on March 4, 2008.
  • 2The offering comprised $450 million of 6.000% Notes due March 1, 2013.
  • 3The offering also included $550 million of 6.875% Notes due March 1, 2018.
  • 4The issuance was registered under a Form S-3, utilizing a shelf registration.
  • 5Key transaction documents, including the underwriting agreement and supplemental indenture, are filed as exhibits.
  • 6This debt issuance impacts the company's capital structure and future interest expenses.

Frequently Asked Questions

Biogen Idec issued a total of $1.0 billion in aggregate principal amount of notes.

The issuance consists of two tranches: $450 million of 6.000% Notes due March 1, 2013, and $550 million of 6.875% Notes due March 1, 2018.

While the filing doesn't explicitly state the purpose, debt offerings like this are typically used for general corporate purposes, which can include funding operations, acquisitions, research and development, or refinancing existing debt. Investors should look to other company communications or subsequent filings for detailed use of proceeds information.

Registering the notes on Form S-3 indicates that Biogen Idec had an effective shelf registration statement on file with the SEC. This allows eligible issuers to efficiently offer and sell securities over time without having to file a new registration statement for each offering, suggesting a pre-approved framework for raising capital.